Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, retinal diseases, and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone919-237-5300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$24.18 million
Profitability
Miscellaneous
Employees353
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Aerie Pharmaceuticals (NASDAQ:AERI) Frequently Asked Questions
What is Aerie Pharmaceuticals' stock symbol?
Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI."
How were Aerie Pharmaceuticals' earnings last quarter?
Aerie Pharmaceuticals Inc (NASDAQ:AERI) issued its quarterly earnings data on Wednesday, August, 7th. The company reported ($0.80) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.87) by $0.07. The business earned $15.84 million during the quarter, compared to analyst estimates of $14.60 million. Aerie Pharmaceuticals had a negative net margin of 478.81% and a negative return on equity of 89.52%. View Aerie Pharmaceuticals' Earnings History.
When is Aerie Pharmaceuticals' next earnings date?
What guidance has Aerie Pharmaceuticals issued on next quarter's earnings?
Aerie Pharmaceuticals updated its FY 2019 earnings guidance on Wednesday, August, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $70-80 million, compared to the consensus revenue estimate of $99.83 million.
What price target have analysts set for AERI?
11 analysts have issued 12-month price objectives for Aerie Pharmaceuticals' stock. Their forecasts range from $45.00 to $105.00. On average, they expect Aerie Pharmaceuticals' share price to reach $61.3636 in the next twelve months. This suggests a possible upside of 177.8% from the stock's current price. View Analyst Price Targets for Aerie Pharmaceuticals.
What is the consensus analysts' recommendation for Aerie Pharmaceuticals?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aerie Pharmaceuticals in the last year. There are currently 1 sell rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aerie Pharmaceuticals.
What are Wall Street analysts saying about Aerie Pharmaceuticals stock?
Here are some recent quotes from research analysts about Aerie Pharmaceuticals stock:
- 1. HC Wainwright analysts commented, "We recently lowered our 2019 revenue to just under $80M vs. prior guidance of $110-120M, and Aeri just lowered to $70-80M. While this looks far below consensus of $98M, we believe current expectation were more in the $85M range, thus guidance is not too far below that. Importantly, we believe the guidance is very achievable, and based only on what the company is already seeing internally in terms of orders, leading indicators and managed care progress, rather than on aggressive market-research based assumptions." (8/8/2019)
- 2. According to Zacks Investment Research, "The uptake of Aerie’s lead drug, Rhopressa, has been strong so far. The drug continues to gain traction with an increase in covered lives under various Medicare plans. The approval of the second drug, Rocklatan, a once-daily, quadruple-action fixed-dose combination of Rhopressa and Xalatan, has boosted the company’s portfolio and should propel sales in the coming quarters as glaucoma is one of the largest segments in the global ophthalmic market. We are also impressed with the company’s efforts to develop and boost pipeline. The company is evaluating possible uses of its proprietary portfolio of Rho Kinase inhibitors beyond glaucoma. Shares have outperformed the industry in the year so far. While the glaucoma market holds potential, Aerie faces stiff competition from existing players and new ones like Vyzulta, among others." (6/28/2019)
- 3. Mizuho analysts commented, "We adjusted our 1Q19 revenue estimate for Rhopressa down but maintain our FY2019 net revenue estimate at the high-end of guidance. We expect Rhopressa Scripts to pick up around June driven by higher anticipated formulary coverage (Medicare Part D going from ~40% currently to ~70%+ in May – guided by management)." (4/21/2019)
Has Aerie Pharmaceuticals been receiving favorable news coverage?
Press coverage about AERI stock has been trending somewhat positive this week, according to InfoTrie. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Aerie Pharmaceuticals earned a news sentiment score of 0.9 on InfoTrie's scale. They also gave media stories about the company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Aerie Pharmaceuticals.
Who are some of Aerie Pharmaceuticals' key competitors?
Some companies that are related to Aerie Pharmaceuticals include Repligen (RGEN), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Ablynx (ABLYF), Allogene Therapeutics (ALLO), Crispr Therapeutics (CRSP), Iovance Biotherapeutics (IOVA), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Regenxbio (RGNX), Audentes Therapeutics (BOLD), Coherus Biosciences (CHRS), Momenta Pharmaceuticals (MNTA) and Alector (ALEC).
What other stocks do shareholders of Aerie Pharmaceuticals own?
Who are Aerie Pharmaceuticals' key executives?
Aerie Pharmaceuticals' management team includes the folowing people:
- Dr. Vicente J. Anido Jr., CEO & Chairman (Age 66)
- Mr. Thomas A. Mitro, Pres & COO (Age 61)
- Dr. Casey C. Kopczynski, Co-Founder & Chief Scientific Officer (Age 58)
- Mr. Richard James Rubino CPA, CFO, Sec. & Treasurer (Age 61)
- Ms. Jessica Crespo CPA, Director of Accounting
Who are Aerie Pharmaceuticals' major shareholders?
Aerie Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.12%), BlackRock Inc. (7.31%), Waddell & Reed Financial Inc. (3.78%), Bank of New York Mellon Corp (3.41%), Pictet Asset Management Ltd. (2.03%) and Pictet Asset Management Ltd. (2.03%). Company insiders that own Aerie Pharmaceuticals stock include Casey C Kopczynski, Foresite Capital Fund Ii, LP, Foresite Capital Management Ii, Gerald D Cagle, Richard J Rubino, Thomas A Mitro and Vicente Anido Jr. View Institutional Ownership Trends for Aerie Pharmaceuticals.
Which institutional investors are selling Aerie Pharmaceuticals stock?
AERI stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Jennison Associates LLC, Invesco Ltd., Bank of America Corp DE, Bank of New York Mellon Corp, Northern Trust Corp, Allianz Asset Management GmbH and Handelsbanken Fonder AB. Company insiders that have sold Aerie Pharmaceuticals company stock in the last year include Casey C Kopczynski and Richard J Rubino. View Insider Buying and Selling for Aerie Pharmaceuticals.
Which institutional investors are buying Aerie Pharmaceuticals stock?
AERI stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., C WorldWide Group Holding A S, Waddell & Reed Financial Inc., Bamco Inc. NY, Nuveen Asset Management LLC, Pictet Asset Management Ltd., Pictet Asset Management Ltd. and Novo Holdings A S. Company insiders that have bought Aerie Pharmaceuticals stock in the last two years include Foresite Capital Fund Ii, LP, Foresite Capital Management Ii, Gerald D Cagle, Richard J Rubino and Vicente Anido Jr. View Insider Buying and Selling for Aerie Pharmaceuticals.
How do I buy shares of Aerie Pharmaceuticals?
Shares of AERI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Aerie Pharmaceuticals' stock price today?
One share of AERI stock can currently be purchased for approximately $22.09.
How big of a company is Aerie Pharmaceuticals?
Aerie Pharmaceuticals has a market capitalization of $1.01 billion and generates $24.18 million in revenue each year. The company earns $-232,570,000.00 in net income (profit) each year or ($4.65) on an earnings per share basis. Aerie Pharmaceuticals employs 353 workers across the globe.View Additional Information About Aerie Pharmaceuticals.
What is Aerie Pharmaceuticals' official website?
How can I contact Aerie Pharmaceuticals?
Aerie Pharmaceuticals' mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The company can be reached via phone at 919-237-5300 or via email at [email protected]
MarketBeat Community Rating for Aerie Pharmaceuticals (NASDAQ AERI)
MarketBeat's community ratings are surveys of what our community members think about Aerie Pharmaceuticals and other stocks. Vote "Outperform" if you believe AERI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AERI will underperform the S&P 500 over the long term. You may vote once every thirty days.
